Blood clot obstructing a vessel cross-section, illustrating fibrin-rich thrombus targeted by thrombolytic therapy for stroke and heart attack treatment.

Syner-KINASE® (urokinase) : a trusted urokinase solution for catheter clearance

Syner-KINASE® (urokinase) : a trusted urokinase solution for catheter clearance

Syner-KINASE (urokinase) is a clinically proven thrombolytic agent designed to dissolve blood clots and restore catheter patency. It delivers clot dissolution through dual administration options – lock or infusion – to help minimise treatment disruptions and reduce the need for catheter replacements.

CLock-icon-home

With a fast-acting 30-minute lock protocol and flexible dosing options, Syner-KINASE enables tailored treatment to meet diverse patient needs. It helps to quickly resolve catheter occlusions and support uninterrupted patient care. It also helps to reduce cost and time burdens to healthcare providers, since the cost of administering a Syner-KINASE lock, plus subsequent infusions, is lower than a catheter replacement.1

Key features and benefits

Key features and benefits

3D molecular visualization of urokinase enzyme interacting with a fibrin clot structure, illustrating the mechanism of thrombolysis in targeted clot degradation therapy.

Proven thrombolytic therapy to help break down a thrombus and restore catheter function2

Syner-Kinase® Human Urokinase vials and packaging in 10,000, 25,000, and 100,000 IU doses, used for intravenous thrombolytic therapy in stroke and heart attack treatment.

Flexible dosing options include 10,000 IU, 25,000 IU and 100,000 IU vials2

Smiling male patient recovering in hospital bed while receiving intravenous therapy

Fast-acting formulation can restore catheter patency with a 30-minute lock protocol, helping to minimise delays and keeping treatment on track

Close-up of healthcare professional administering intravenous catheter for thrombolytic drug delivery in a clinical setting

Dual administration options allow use as a catheter lock – a urokinase injection into the catheter to clear intraluminal occlusions – or as a urokinase infusion to dissolve clots on both the inside and outside of the catheter2

Gloved hand opening laboratory refrigerator containing temperature-sensitive medical vials, emphasizing proper storage conditions for injectable thrombolytic drugs.

No cold chain storage required, enabling straightforward storage and handling in clinical settings2

Discover more about Syner-KINASE

Discover more about Syner-KINASE

Blood clot obstructing a vessel cross-section, illustrating fibrin-rich thrombus targeted by thrombolytic therapy for stroke and heart attack treatment.

Learn about catheter thrombosis and why thrombolytic therapy is essential

Syner-Kinase® Human Urokinase vials and packaging in 10,000, 25,000, and 100,000 IU doses

Find out more about
Syner-KINASE®

Audience attending a medical conference , with expert speakers on stage discussing innovations in thrombolytic therapy and cardiovascular care.

Watch expert-led discussions on thrombolysis for catheter blockages

Have questions or need more information?

Have questions or need more information?

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. 

Adverse events should also be reported to Syner-Med (PP) Ltd. Tel: +44 (0)208 655 6380

For Syner-KINASE prescribing information, click here

References

  1. Syner-Med. Data on File. Resource Impact Model Evaluating Syner-Kinase® for Catheter Occlusion Management in NHS Settings. Model Version 1.0.; 2025.
  2. Syner-Medica Ltd. 2006. Syner-KINASE 100,000 IU powder for solution for injection/infusion – summary of product characteristics (SmPC). https://www.medicines.org.uk/emc/product/7565/smpc/print